ARTICLE | Distillery Therapeutics
Neurology
December 12, 2018 4:12 PM UTC
Patient sample and mouse studies suggest inhibiting LGMN-mediated cleavage of SRPK2 could help treat AD, frontotemporal dementia (FTD) and PSP. In brain tissue samples from patients with AD, FTD or PS...